Literature DB >> 34210292

Longitudinal change in lung function and subsequent risks of cardiovascular events: evidence from four prospective cohort studies.

Yun-Jiu Cheng1,2, Zhen-Guang Chen3, Zhu-Yu Li4, Wei-Yi Mei5,6, Wen-Tao Bi7,8, Dong-Ling Luo9.   

Abstract

BACKGROUND: Lung function is constantly changing over the life course. Although the relation of cross-sectional lung function measure and adverse outcomes has been reported, data on longitudinal change and subsequent cardiovascular (CV) events risks are scarce. Therefore, this study is to determine the association of longitudinal change in lung function and subsequent cardiovascular risks.
METHODS: This study analyzed the data from four prospective cohorts. Subjects with at least two lung function tests were included. We calculated the rate of forced respiratory volume in 1 s (FEV1) and forced vital capacity (FVC) decline for each subject and categorized them into quartiles. The primary outcome was CV events, defined as a composite of coronary heart disease (CHD), chronic heart failure (CHF), stroke, and any CV death. Cox proportional hazards regression and restricted cubic spline models were applied.
RESULTS: The final sample comprised 12,899 participants (mean age 48.58 years; 43.61% male). Following an average of 14.79 (10.69) years, 3950 CV events occurred. Compared with the highest FEV1 quartile (Q4), the multivariable HRs for the lowest (Q1), 2nd (Q2), and 3rd quartiles (Q3) were 1.33 (95%CI 1.19, 1.49), 1.30 (1.16, 1.46), and 1.07 (0.95, 1.21), respectively. Likewise, compared with the reference quartile (Q4), the group that experienced a faster decline in FVC had higher HRs for CV events (1.06 [95%CI 0.94-1.20] for Q3, 1.15 [1.02-1.30] for Q2, and 1.28 [1.14-1.44] for Q1). The association remained robust across a series of sensitivity analyses and nearly all subgroups but was more evident in subjects < 60 years.
CONCLUSIONS: We observed a monotonic increase in risks of CV events with a faster decline in FEV1 and FVC. These findings emphasize the value of periodic evaluation of lung function and open new opportunities for disease prevention.

Entities:  

Keywords:  Cardiovascular events; Change; Coronary heart disease; Heart failure; Lung function

Year:  2021        PMID: 34210292     DOI: 10.1186/s12916-021-02023-3

Source DB:  PubMed          Journal:  BMC Med        ISSN: 1741-7015            Impact factor:   8.775


  37 in total

1.  Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994.

Authors:  D M Mannino; R C Gagnon; T L Petty; E Lydick
Journal:  Arch Intern Med       Date:  2000-06-12

2.  Chronic obstructive pulmonary disease: a slowly progressive cardiovascular disease masked by its pulmonary effects?

Authors:  Frans H Rutten; Arno W Hoes
Journal:  Eur J Heart Fail       Date:  2012-02-25       Impact factor: 15.534

3.  Impaired pulmonary function is a risk predictor for sudden cardiac death in men.

Authors:  Sudhir Kurl; Sae Young Jae; Jussi Kauhanen; Kimmo Ronkainen; Jari A Laukkanen
Journal:  Ann Med       Date:  2015-07-10       Impact factor: 4.709

4.  Lung function and risk of myocardial infarction and sudden cardiac death.

Authors:  G D Friedman; A L Klatsky; A B Siegelaub
Journal:  N Engl J Med       Date:  1976-05-13       Impact factor: 91.245

5.  Lung function and risk for heart failure among older adults: the Health ABC Study.

Authors:  Vasiliki V Georgiopoulou; Andreas P Kalogeropoulos; Bruce M Psaty; Nicolas Rodondi; Douglas C Bauer; Abida B Butler; Annemarie Koster; Andrew L Smith; Tamara B Harris; Anne B Newman; Stephen B Kritchevsky; Javed Butler
Journal:  Am J Med       Date:  2011-04       Impact factor: 4.965

6.  Impaired lung function and subclinical atherosclerosis. The ARIC Study.

Authors:  Emily B Schroeder; Verna Lamar Welch; Gregory W Evans; Gerardo Heiss
Journal:  Atherosclerosis       Date:  2005-01-25       Impact factor: 5.162

7.  Association of lung function with cognitive decline and dementia: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  S S Pathan; R F Gottesman; T H Mosley; D S Knopman; A R Sharrett; A Alonso
Journal:  Eur J Neurol       Date:  2011-01-18       Impact factor: 6.089

8.  Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study.

Authors:  MyLinh Duong; Shofiqul Islam; Sumathy Rangarajan; Darryl Leong; Om Kurmi; Koon Teo; Kieran Killian; Gilles Dagenais; Scott Lear; Andreas Wielgosz; Sanjeev Nair; Viswanathan Mohan; Prem Mony; Rajeev Gupta; Rajesh Kumar; Omar Rahman; Khalid Yusoff; Johannes Lodewykus du Plessis; Ehimario U Igumbor; Jephat Chifamba; Wei Li; Yin Lu; Fumin Zhi; Ruohua Yan; Romaina Iqbal; Noorhassim Ismail; Katarzyna Zatonska; Kubilay Karsidag; Annika Rosengren; Ahmad Bahonar; Afazalhussein Yusufali; Pablo M Lamelas; Alvaro Avezum; Patricio Lopez-Jaramillo; Fernando Lanas; Paul M O'Byrne; Salim Yusuf
Journal:  Lancet Glob Health       Date:  2019-05       Impact factor: 26.763

9.  Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study.

Authors:  D J Hole; G C Watt; G Davey-Smith; C L Hart; C R Gillis; V M Hawthorne
Journal:  BMJ       Date:  1996-09-21

10.  Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Jingjing Li; Sunil K Agarwal; Alvaro Alonso; Saul Blecker; Alanna M Chamberlain; Stephanie J London; Laura R Loehr; Ann Marie McNeill; Charles Poole; Elsayed Z Soliman; Gerardo Heiss
Journal:  Circulation       Date:  2013-12-16       Impact factor: 29.690

View more
  1 in total

1.  Impact of Spirometrically Confirmed Chronic Obstructive Pulmonary Disease on Arterial Stiffness and Surfactant Protein D After Percutaneous Coronary Intervention. The CATEPOC Study.

Authors:  Komal Malik; Susana Diaz-Coto; Maria de la Asunción Villaverde; Pablo Martinez-Camblor; Annie Navarro-Rolon; Francisco Pujalte; Alejandro De la Sierra; Pere Almagro
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-10-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.